Literature DB >> 32299831

Patent foramen ovale.

Vafa Alakbarzade1, Tracey Keteepe-Arachi2, Nazia Karsan2, Robin Ray2, Anthony C Pereira2.   

Abstract

Patent foramen ovale (PFO) is the most common anatomical cause of an interatrial shunt. It is usually asymptomatic but may cause paradoxical embolism, manifesting as stroke, myocardial infarction or visceral/peripheral ischaemia. PFO is a risk factor for stroke and may be associated with migraine with aura. New evidence suggests PFO closure reduces the risk of recurrent ischaemic stroke in a highly selected population of stroke survivors: those aged 60 years or younger with a cryptogenic stroke syndrome, a large right-to-left shunt, an atrial septal aneurysm and no evidence of atrial fibrillation. They benefit from percutaneous PFO closure in addition to antiplatelet therapy, rather than antiplatelet therapy alone. Current evidence does not support PFO closure in the treatment of migraine. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiology; cerebrovascular disease; interventional; migraine; stroke

Mesh:

Year:  2020        PMID: 32299831     DOI: 10.1136/practneurol-2019-002450

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  2 in total

1.  A Nomogram for the Prediction of Cessation of Migraine Among Patients With Patent Foramen Ovale After Percutaneous Closure.

Authors:  Enfa Zhao; Hang Xie; Yushun Zhang
Journal:  Front Neurol       Date:  2020-10-23       Impact factor: 4.003

2.  When orofacial pain needs a heart repair.

Authors:  Daniela Adamo; Elena Calabria; Noemi Coppola; Giuseppe Pecoraro; Giuseppe Buono; Michele Davide Mignogna
Journal:  Clin Exp Dent Res       Date:  2020-11-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.